Shopping Cart
Remove All
Your shopping cart is currently empty
FZ-A038
Copy Product Info
🥰Excellent
Synonyms:
Catalog No. T9901A-490 Copy Product Info
🥰Excellent
FZ-A038 is a humanized monoclonal antibody targeting Delta-like ligand 3 (DLL3). DLL3 is specifically overexpressed in small cell lung cancer (SCLC) and neuroendocrine carcinomas, with its signaling activation involving proteolytic cleavage by Gamma-secretase. FZ-A038 binds to the extracellular domain of DLL3 with high affinity and induces rapid internalization. As the antibody component of the antibody-drug conjugate (ADC) FZ-AD005, it delivers a conjugated Topoisomerase I inhibitor (an exatecan derivative) into tumor cells via internalization, inducing DNA damage and exerting potent anti-tumor activity.
FZ-A038
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | Inquiry | Inquiry | |
| 5 mg | Inquiry | Inquiry | Inquiry |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Antibody Information
Storage & Solubility Information
| Description | FZ-A038 is a humanized monoclonal antibody targeting Delta-like ligand 3 (DLL3). DLL3 is specifically overexpressed in small cell lung cancer (SCLC) and neuroendocrine carcinomas, with its signaling activation involving proteolytic cleavage by Gamma-secretase. FZ-A038 binds to the extracellular domain of DLL3 with high affinity and induces rapid internalization. As the antibody component of the antibody-drug conjugate (ADC) FZ-AD005, it delivers a conjugated Topoisomerase I inhibitor (an exatecan derivative) into tumor cells via internalization, inducing DNA damage and exerting potent anti-tumor activity. |
| In vitro | FZ-A038 binds human DLL3 with high affinity and specificity, undergoing rapid internalization in NCI-H69 and NCI-H187 cells. In ADC format (FZ-AD005), it exhibits potent cytotoxicity (sub-nanomolar IC50) by inducing DNA double-strand breaks and subsequent apoptosis in DLL3+ tumor cells [1]. |
| In vivo | In pharmacological studies using SCLC and neuroendocrine carcinoma xenograft mouse models, systemic administration of the FZ-AD005 ADC (containing the FZ-A038 arm) results in significant and durable tumor regression [1]. |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | DLL3 |
| Isotype | IgG1-LFLE-PS |
| Storage | Store at low temperature Store at -20°C Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: FZ-A038 in vivo | FZ-A038 in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.